Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.

# Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.  **Read the full article:** [CNBC](https://www.cnbc.com/2026/11/06/moderna-mrna-earnings-q3-2026.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*